Malaria research and its influence on anti-malarial drug policy in Malawi: a case study

Home
→
HSRC Research Outputs
→
Public
→
View Item

Mwendera, C., De Jager, C., Longwe, H., Phiri, K., Hongoro, C. & Mutero, C.M. (2016) Malaria research and its influence on anti-malarial drug policy in Malawi: a case study. Health Research Policy and Systems. 14(1):Online. http://hdl.handle.net/20.500.11910/10288

http://hdl.handle.net/20.500.11910/10288

Abstract:

In 1993, Malawi changed its first-line anti-malarial treatment for uncomplicated malaria from chloroquine to sulfadoxine-pyrimethamine (SP), and in 2007, it changed from SP to lumefantrine-artemether. The change in 1993 raised concerns about whether it had occurred timely and whether it had potentially led to early development of Plasmodium falciparum resistance to SP. This case study examined evidence from Malawi in order to assess if the policy changes were justifiable and supported by evidence.

Reference:

If you would like to obtain a copy of this Research Output, please contact the Research Outputs curators at researchoutputs@hsrc.ac.za

Attribution-NonCommercial
CC BY-NC

This license lets others remix, adapt, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.

14 Jun 2016

MALARIA
MALAWI
DRUG USE
POLICY IMPLEMENTATION

Show full item record

Files in this item

9244.pdf